Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06424834 | RECRUITING | Angina Pectoris

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
Sponsor:

Stanford University

Information provided by (Responsible Party):

Christopher Chi-Yuen Wong

Brief Summary:

The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.

Condition or disease

Angina Pectoris

Microvascular Angina

Vasospastic Angina

Myocardial Bridge of Coronary Artery

Intervention/treatment

Amlodipine

Nebivolol

Placebo

Phase

PHASE2

PHASE3

Study Type : INTERVENTIONAL
Estimated Enrollment : 150 participants
Masking : QUADRUPLE
Primary Purpose : TREATMENT
Official Title : A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study
Actual Study Start Date : 2024-10-10
Estimated Primary Completion Date : 2026-12
Estimated Study Completion Date : 2026-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.
  • Specific inclusion criteria for randomization
    • * Absence of significant epicardial coronary artery disease on angiography
    • * Fractional flow reserve \> 0.80
    • And ≥ 1 of the following
      • * Epicardial coronary spasm on acetylcholine testing
      • * Microvascular spasm on acetylcholine testing
      • * Coronary flow reserve \< 2.5
      • * Index of microcirculatory resistance ≥ 25
      • * Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76
      Exclusion Criteria
      • * Acute coronary syndrome less than one week prior to enrolment
      • * Cardiomyopathy
      • * Contraindications to beta-blockers or calcium channel blockers
      • * Baseline systolic blood pressure \< 95 mmHg
      • * Baseline heart rate \< 55 bpm
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Location Details

NCT06424834

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

Stanford Hospital

Palo Alto, California, United States, 94304